FDA Approves Mirvetuximab Soravtansine for Ovarian Cancer

This is an accelerated approval for use in patients with folate receptor alpha–positive disease, identified by an assay that was approved alongside the drug.
FDA Approvals

source https://www.medscape.com/viewarticle/984055?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension